Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2021

19.09.2020 | Clinical trial

Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan

verfasst von: Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto, Hideo Yasunaga

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although both localization of breast cancer and body mass index (BMI) are associated with prognosis, the association between localization of breast cancer and BMI remains unclear. This study aimed to investigate the association between localization of breast cancer and BMI at diagnosis.

Methods

Patients who underwent surgery for stage 0–III breast cancer July 2010–March 2017 were identified retrospectively in a Japanese nationwide inpatient database. Multinomial logistic regression analyses adjusting for patient’s age were conducted to compare the outcomes among five BMI groups: < 18.5 kg/m2 (n = 31,724; 9.3%), 18.5–24.9 kg/m2 (n = 218,244; 64.3%), 25.0–29.9 kg/m2 (n = 69,813; 20.6%), 30.0–34.9 kg/m2 (n = 16,052; 4.7%), and ≥ 35.0 kg/m2 (n = 3716; 1.1%). The outcomes were the quadrant and side of the breast where tumors were detected.

Results

In total, about half of the patients had breast cancer in the upper-outer quadrant (49.7%) and in the left breast (51.1%). In the multinomial analysis, BMI ≥ 25.0 kg/m2 was associated with the occurrence of breast cancer in the upper-inner and lower-outer quadrants and in the central area, whereas BMI < 18.5 kg/m2 was associated with the occurrence of breast cancer in the central area only. The side of breast cancer did not differ significantly among the five BMI groups.

Conclusions

Localization of breast cancer was associated with BMI in this large nationwide cohort. The findings may benefit patients’ self-checks and doctors’ examinations, potentially resulting in early detection and treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
9.
Zurück zum Zitat Lohrisch C, Jackson J, Jones A, Mates D, Olivotto IA (2000) Relationship between tumor location and relapse in 6,781 women with early invasive breast cancer. J Clin Oncol 18:2828–2835CrossRef Lohrisch C, Jackson J, Jones A, Mates D, Olivotto IA (2000) Relationship between tumor location and relapse in 6,781 women with early invasive breast cancer. J Clin Oncol 18:2828–2835CrossRef
16.
Zurück zum Zitat Yasunaga H (2019) Real world data in Japan: chapter II the diagnosis procedure combination database. Ann Clin Epidemiol 1:76–79CrossRef Yasunaga H (2019) Real world data in Japan: chapter II the diagnosis procedure combination database. Ann Clin Epidemiol 1:76–79CrossRef
18.
Zurück zum Zitat Yoko A, Shizukiyo I, Tadao G, Kazunori K, Yosikazu N, Kajii E (2006) Age at menopause and mortality in Japan: the Jichi Medical School Cohort Study. Epidemiology 16:1–5CrossRef Yoko A, Shizukiyo I, Tadao G, Kazunori K, Yosikazu N, Kajii E (2006) Age at menopause and mortality in Japan: the Jichi Medical School Cohort Study. Epidemiology 16:1–5CrossRef
22.
Zurück zum Zitat Boyd NF, Guo H, Martin LJ et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 18:227–236CrossRef Boyd NF, Guo H, Martin LJ et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 18:227–236CrossRef
26.
Zurück zum Zitat Dominkovic MD, Ivanac G, Bojanic K et al (2020) Exploring association of breast pain, pregnancy, and body mass index with breast tissue elasticity in healthy women: glandular and fat differences. Diagnostics 10:393CrossRef Dominkovic MD, Ivanac G, Bojanic K et al (2020) Exploring association of breast pain, pregnancy, and body mass index with breast tissue elasticity in healthy women: glandular and fat differences. Diagnostics 10:393CrossRef
30.
Zurück zum Zitat Preston DL, Mattsson A, Holmberg E et al (2002) Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 158:220–235CrossRef Preston DL, Mattsson A, Holmberg E et al (2002) Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 158:220–235CrossRef
31.
Zurück zum Zitat Alqahtani SJM, Welbourn R, Thomson K, Knapp KM (2019) Increased radiation dose and projected radiation-related lifetime cancer risk in patients with obesity due to projection radiography. J Radiol Prot 39:38–53CrossRef Alqahtani SJM, Welbourn R, Thomson K, Knapp KM (2019) Increased radiation dose and projected radiation-related lifetime cancer risk in patients with obesity due to projection radiography. J Radiol Prot 39:38–53CrossRef
Metadaten
Titel
Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan
verfasst von
Takaaki Konishi
Michimasa Fujiogi
Nobuaki Michihata
Kojiro Morita
Hiroki Matsui
Kiyohide Fushimi
Masahiko Tanabe
Yasuyuki Seto
Hideo Yasunaga
Publikationsdatum
19.09.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05934-6

Weitere Artikel der Ausgabe 1/2021

Breast Cancer Research and Treatment 1/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.